Stockscreener 앱 받기
27.93
1.27%
0.3199
전일 마감가:
$27.61
열려 있는:
$27.8
하루 거래량:
5.23M
Relative Volume:
0.52
시가총액:
$10.62B
수익:
$5.06B
순이익/손실:
$-2.22B
주가수익비율:
-4.799
EPS:
-5.82
순현금흐름:
$-3.96B
1주 성능:
+1.82%
1개월 성능:
+11.35%
6개월 성능:
-47.53%
1년 성능:
-77.63%
1일 변동 폭
$27.18
$28.52
1주일 범위
$26.06
$28.65
52주 변동 폭
$23.15
$170.47
모더나 Stock (MRNA) Company Profile
명칭
Moderna Inc
전화
(617) 714-6500
주소
325 BINNEY STREET, CAMBRIDGE
MRNA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
27.94 | 10.62B | 5.06B | -2.22B | -3.96B | -5.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
503.20 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
607.32 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.34 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.15 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.06 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
모더나 Stock (MRNA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-13 | 개시 | Citigroup | Neutral |
| 2025-02-18 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2025-01-29 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-12-18 | 다운그레이드 | Argus | Buy → Hold |
| 2024-12-10 | 재개 | BofA Securities | Underperform |
| 2024-11-19 | 개시 | Berenberg | Hold |
| 2024-11-18 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-11-15 | 개시 | Wolfe Research | Underperform |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-09-13 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2024-09-13 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-09-13 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-08-28 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2024-08-07 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2024-08-05 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | 다운그레이드 | HSBC Securities | Hold → Reduce |
| 2024-01-02 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2023-11-29 | 개시 | Canaccord Genuity | Hold |
| 2023-11-03 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2023-11-02 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2023-08-04 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2023-07-24 | 개시 | William Blair | Mkt Perform |
| 2023-07-14 | 개시 | HSBC Securities | Reduce |
| 2023-06-26 | 업그레이드 | UBS | Neutral → Buy |
| 2023-04-26 | 개시 | Guggenheim | Neutral |
| 2023-03-13 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | 개시 | RBC Capital Mkts | Outperform |
| 2023-02-24 | 다운그레이드 | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-12-14 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | 업그레이드 | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2022-02-01 | 업그레이드 | Redburn | Sell → Neutral |
| 2022-01-26 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2022-01-21 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2022-01-21 | 개시 | UBS | Neutral |
| 2021-12-07 | 개시 | Cowen | Market Perform |
| 2021-11-09 | 개시 | Wolfe Research | Outperform |
| 2021-10-22 | 개시 | Deutsche Bank | Sell |
| 2021-10-15 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-08-06 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | 재확인 | Jefferies | Hold |
| 2021-02-01 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-12-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-12-16 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | 다운그레이드 | Needham | Buy → Hold |
| 2020-11-23 | 개시 | Wells Fargo | Equal Weight |
| 2020-11-17 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | 개시 | SVB Leerink | Mkt Perform |
| 2020-07-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-07-13 | 개시 | Jefferies | Buy |
| 2020-06-30 | 개시 | Argus | Buy |
| 2020-06-08 | 개시 | Barclays | Overweight |
| 2020-04-30 | 개시 | BMO Capital Markets | Outperform |
| 2020-03-05 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | 재개 | BofA/Merrill | Buy |
| 2019-10-25 | 개시 | ROTH Capital | Buy |
| 2019-04-05 | 개시 | Chardan Capital Markets | Buy |
모두보기
모더나 주식(MRNA)의 최신 뉴스
Ex-Moderna brand chief Kate Cronin joins Medtronic Diabetes as marketing lead - Medical Marketing and Media
Moderna, Inc. (NASDAQ:MRNA) Shares Sold by PDT Partners LLC - MarketBeat
Northern Trust Corp Purchases 354,871 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Kovitz Investment Group Partners LLC - MarketBeat
Lido Advisors LLC Boosts Stock Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
The Manufacturers Life Insurance Company Acquires 267,990 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna Stock Crumbles As Vaccine Troubles Rattle Its Topline - MSN
Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Pinebridge Investments L.P. - MarketBeat
Moderna Q1 Earnings Ahead: Analysts expect loss amid increased regulatory scrutiny - MSN
Price T Rowe Associates Inc. MD Cuts Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Dimensional Fund Advisors LP Has $69.34 Million Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – MRNA - ACCESS Newswire
Public Employees Retirement Association of Colorado Lowers Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Envestnet Asset Management Inc. Trims Stock Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Aquatic Capital Management LLC - MarketBeat
UBS Analyst Lowers Price Target for MRNA, Maintains Buy Rating | - GuruFocus
XTX Topco Ltd Decreases Stock Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Barclays Lowers Price Target on Moderna (MRNA) to $40.00 | MRNA Stock News - GuruFocus
Moderna Pivots To Increase Focus On Cancer Amid US Vaccine Policy Changes - insights.citeline.com
Susquehanna Fundamental Investments LLC Invests $16.04 Million in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna (MRNA) Price Target Lowered by RBC Capital | MRNA Stock News - GuruFocus
Moderna (MRNA) Target Price Cut by RBC Capital Amid Financial Up - GuruFocus
Moderna (NasdaqGS:MRNA) Reports Decrease in Q1 Revenue and Net Loss - Yahoo Finance
Moderna faces long-term threat from NIH’s universal vaccine initiative, Jefferies says - Proactive Investors
Moderna (MRNA) Downgraded as Financial Strains Emerge - GuruFocus
UBS Adjusts Price Target on Moderna to $70 From $78, Maintains Buy Rating - marketscreener.com
Moderna (MRNA) Analyst Maintains Rating but Lowers Price Target - GuruFocus
UBS Revises Price Target for Moderna (MRNA) Due to Vaccine Uncer - GuruFocus
Moderna (MRNA) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance
Moderna Earnings Top Estimates. Why the Stock Is Dropping. - Barron's
Moderna price target lowered to $28 from $32 at RBC Capital - TipRanks
Moderna, Inc. (NASDAQ:MRNA) Q1 2025 Earnings Call Transcript - Insider Monkey
Berenberg holds Moderna stock with $30 target amid cost cuts - Investing.com
Berenberg holds Moderna stock with $30 target amid cost cuts By Investing.com - Investing.com UK
State of Tennessee Department of Treasury Sells 27,726 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna Inc (MRNA) Q1 2025 Earnings Call Highlights: Navigating Challenges with Strategic Cost ... - Yahoo Finance
Moderna Inc (MRNA) Q1 2025 Earnings Call Highlights: Navigating - GuruFocus
Press Release Distribution & PR Platform - ACCESS Newswire
Moderna’s Q1 2025: Revenue Decline and Strategic Focus - TipRanks
Moderna Punts On US Vaccine Policy Changes, Will Focus More On Cancer - insights.citeline.com
Moderna shares fall on vaccine sales miss, delay in FDA review - The Boston Globe
Moderna combination flu, COVID shot delayed amid FDA scrutiny - BioPharma Dive
Moderna (MRNA) Price Target Cut by Citi Analyst Amid Concerns | - GuruFocus
Moderna (MRNA) Price Target Cut by RBC Capital Following Earnings Report | MRNA Stock News - GuruFocus
Moderna Cuts Costs as COVID Sales Slump - Yahoo Finance
Citigroup Cuts Moderna Price Target to $32 From $40 - marketscreener.com
Moderna, facing revenue misses and political headwinds, disappoints Wall Street - Endpoints News
Moderna: Regulatory Hurdles And Market Challenges Prompt Downgrade To Sell (NASDAQ:MRNA) - Seeking Alpha
Moderna Expands Cost-Cutting Program By Up To $1.7 Billion, FDA Approval For Flu/COVID-19 Combo Shot Delayed Into 2026 - Benzinga
Moderna says FDA has been constructive, but delays flu/COVID shot - Reuters
Moderna's Revenue Surpasses Expectations Despite First-Quarter Loss - Finimize
모더나 (MRNA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
모더나 주식 (MRNA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| SAGAN PAUL | Director |
Mar 03 '25 |
Buy |
31.76 |
31,620 |
1,004,251 |
312,027 |
| Klinger Shannon Thyme | Chief Legal Officer |
Dec 09 '24 |
Sale |
44.68 |
529 |
23,637 |
20,446 |
0.60%
3.33%
자본화:
|
볼륨(24시간):